Computer-aided quantitative bone scan assessment of prostate cancer treatment response

Nuclear Medicine Communications

Volumn 33, Issue 4, 2012, Pages 384-394

  Brown, Matthew S ^a   Chu, Gregory H ^a   Kim, Hyun J ^a   Allen Auerbach, Martin ^b   Poon, Cheryce ^b   Bridges, Juliette ^c   Vidovic, Adria ^c   Ramakrishna, Bharath ^a   Ho, Judy ^a   Morris, Michael J ^d,e,g   Larson, Steven M ^f   Scher, Howard I ^d,e,g   Goldin, Jonathan G ^a  

^a Center for Computer Vision and Imaging Biomarker   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MedQIA LLC   (United States)

^d Genitourinary Oncology Service   (United States)

^e Sidney Kimmel Center for Prostate and Urologic Cancers   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

bone neoplasms; bone scan; computer assisted detection; computer assisted image processing; prostate cancer; radionuclide imaging

Indexed keywords

CABOZANTINIB;

ARTICLE; BONE LESION; BONE SCINTISCANNING; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER AIDED DETECTION SYSTEM; COMPUTER ASSISTED SCINTIGRAPHY; COMPUTER ASSISTED THERAPY; CONTROLLED STUDY; HUMAN; IMAGE ANALYSIS; MALE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR VOLUME;

ANILIDES; BONE NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; PROSTATIC NEOPLASMS; PYRIDINES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; TREATMENT OUTCOME; TUMOR BURDEN; WHOLE BODY IMAGING;

EID: 84863230043     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283503ebf     Document Type: Article

References (26)

1. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88 (12 Suppl):2989-2994. (Pubitemid 30413181)
2. Sonpavde G, Pond GR, Berry WR, de Wit R, Eisenberger MA, Tannock IF, et al. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer 2011; 117:3963-3971.
3. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res 2008; 14:1599-1602. (Pubitemid 351469442)
4. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165-176. (Pubitemid 32452017)
5. Coleman R, Heidenreich A, Bell R. Managing metastatic bone disease: three case studies. Semin Oncol 2004; 31 (5 Suppl 10):83-86. (Pubitemid 39370117)
6. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999; 17: 948-957. (Pubitemid 29109328)
7. Peters AM, Bomanji J, Costa DC, Ell PJ, Gordon I, Henderson BL, et al. Clinical audit in nuclear medicine. Nucl Med Commun 2004; 25: 97-103. (Pubitemid 38315410)
8. Sadik M, Suurkula M, Höglund P, Järund A, Edenbrandt L. Quality of planar whole-body bone scan interpretations - nationwide survey. Eur J Nucl Med Mol Imaging 2008; 35:1464-1472.
9. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castrationresistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011; 17:4854-4861.
10. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005; 11:5223-5232. (Pubitemid 41003710)
11. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-1159.
12. Erdi YE, Humm JL, Imbriaco M, Yeung H, Larson SM. Quantitative bone metastases analysis based on image segmentation. J Nucl Med 1997; 38:1401-1406. (Pubitemid 27386199)
13. Yin TK, Chiu NT. A computer-aided diagnosis for locating abnormalities in bone scintigraphy by a fuzzy system with a three-step minimization approach. IEEE Trans Med Imaging 2004; 23:639-654.
14. Sadik M, Jakobsson D, Olofsson F, Ohlsson M, Suurkula M, Edenbrandt L. A new computer-based decision-support system for the interpretation of bone scans. Nucl Med Commun 2006; 27:417-423. (Pubitemid 44309719)
15. Jeong CB, Kim KG, Kim TS, Kim SK. Comparison of image enhancement methods for the effective diagnosis in successive whole-body bone scans. J Digit Imaging 2011; 24:424-436.
16. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res 1998; 4: 1765-1772. (Pubitemid 28304740)
17. Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 2003; 88:195-201. (Pubitemid 36255835)
18. Yahara J, Noguchi M, Noda S. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment. BJU Int 2003; 92:379-384.
19. Morris MJ, Jia X, Larson SM, Kelly A, Mezheritzky I, Stephenson RD, et al. Post-treatment serial bone scan index (BSI) as an outcome measure predicting survival. Presented at: Genitourinary Cancers Symposium 2008; February 14-16, 2008; Alexandria, VA, abstract 189.
20. You WK, Sennino B,Williamson CW, Falco n B, Hashizume H, Yao LC, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011; 71:4758-4768.
21. Gordon MS, Vogelzang NJ, Schoffski P, Daud A, Spira AI, O'Keeffe BA, et al. Activity of cabozantinib (XL184) in soft tissue and bone: results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J Clin Oncol 2011; 29:3010 (Suppl; abstract 3010).
22. Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky AA, Gordon MS, et al. Cabozantinib (XL184) in metastatic castration resistant prostate cancer (mCRPC): results from a Phase 2 randomized discontinuation trial. J Clin Oncol 2011; 29:4516 (Suppl; abstract 4516).
23. Mattes D, Haynor DR, Vesselle H, Lewellen TK, Eubank W. PET-CT image registration in the chest using free-form deformations. IEEE Trans Med Imaging 2003; 22:120-128.
24. Cachier P, Pennec X, Ayache N. Fast nonrigid matching by gradient descent: study and improvements of the "demons" algorithm. Research Report 3706, INRIA, June 1999. Available at http://hal.inria.fr/docs/00/07/29/ 62/PDF/RR-3706.pdf. [Accessed 2 August 2011].
25. Yoo TS, Ackerman MJ, Lorensen WE, Schroeder W, Chalana V, Aylward S, et al. Engineering and algorithm design for an image processing API: a technical report on ITK - the Insight Toolkit. In: Westwood JD, Hoffman HM, Mogel GT, editors. Medicine meets virtual reality. Amsterdam: IOS Press; 2002. pp. 586-592.
26. Rossing N, Munck O, Nielsen SP, Andersen KW. What do early bone scans tell about breast cancer patients? Eur J Cancer Clin Oncol 1982; 18: 629-636. (Pubitemid 12056998)